Influenza Vaccines Available During the 2020–21 Season

Vaccines Available

Influenza vaccine options available in the United States this season include the following: Afluria®, FluariX®, FluLaval®, Fluzone®, Flucelvax®, Fluzone High-Dose®, Fluarix®, FluMist®, and Flublok®, and Flumist®. The Alaska Immunization Program will supply 10 presentations of quadrivalent influenza vaccine this season (Table).

2020–21 Influenza Vaccine Composition†

Egg-based influenza vaccines (i.e., vaccines other than ccIIV4 and RIV4) will contain hemagglutinin (HA) derived from:
- influenza A/Guangdong/361/2019 (H1N1) pdm09-like virus
- influenza A/Hong Kong/2671/2019 (H3N2)-like virus
- influenza B/Washington/02/2019 (Victoria lineage)-like virus
- for quadrivalent egg-based vaccines only, an influenza B/Phuket/307/2013 (Yamagata lineage)-like virus

Cell culture–based inactivated (ccIIV4) and recombinant (RIV4) influenza vaccines will contain HA derived from:
- influenza A/Hawaii/70/2019 (H1N1) pdm09-like virus
- influenza A/Hong Kong/45/2019 (H1N2)-like virus
- influenza B/Washington/02/2019 (Victoria lineage)-like virus
- influenza B/Phuket/307/2013 (Yamagata lineage)-like virus

Influenza Vaccine Abbreviations‡

- IIV: inactivated influenza vaccine
- RIV: recombinant influenza vaccine
- LAIV: live attenuated influenza vaccine
- cc: prefix indicating cell culture–based vaccine (e.g., ccIIV4)
- a: prefix indicating adherent vaccine (e.g., allVX)
- Numeric suffix specifies the number of hemagglutinin (HA) antigens in the vaccine (e.g., IIV3=trivalent, and IIV4=quadrivalent)

Storage

All influenza vaccine should be stored at 36°–46°F (2°–8°C), and should not be frozen.

Inactivated Influenza Vaccines (IIV)

Inactivated influenza vaccine contains inactivated viruses. The IIV vaccines available this season are as follows:
- Egg-based (IIV4): Afluria®, FluariX®, FluLaval®, and Fluzone® are licensed for persons aged ≥6 months.†
- Cell culture-based (ccIIV4): Flucelvax® is licensed for persons aged ≥2 years (note: the influenza viruses are propagated in Madin–Darby canine kidney cells instead of eggs).
- Egg-based high dose (HD-IIV4): Fluzone High-Dose® is licensed for persons aged ≥65 years.‡
- Egg-based with MF59 adjuvant (allV3 or allIV4): Fluarix® is licensed for persons aged ≥65 years.‡

Recombinant Influenza Vaccine (RIV)

Flublok® (RIV4) contains recombinant HA produced in an insect cell line using genetic sequences from cell-derived influenza viruses and is manufactured without the use of influenza viruses or eggs. Flublok® (RIV4) may be used in persons aged ≥18 years.‡

Live-Attenuated Influenza Vaccine (LAIV)

Flumist (LAIV4) contains live, attenuated (weakened), temperature-sensitive (cold-adapted) viruses that are able to replicate efficiently only at temperatures present in the nasal mucosa. If the recipient sneezes immediately after administration, the dose should not be repeated. Flumist (LAIV4) is available for nonpregnant persons aged 2 through 49 years.‡

References


2. U.S. Food and Drug Administration, Vaccines, Blood, and Biologics: Manufacturer Package Inserts. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/U CM093833


Table. Alaska Immunization Program Supplied Influenza Vaccines

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Manufacturer</th>
<th>Presentation</th>
<th>Age Indication</th>
<th>HA (IIVs / RIV4) or virus count (VAIV4) for each vaccine virus (per dose)</th>
<th>Route</th>
<th>Mercury (from thimerosal)</th>
<th>Late Season Arrival</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IIVs (IIV4) / RIV4 or virus count (VAIV4) for each vaccine virus (per dose)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard dose, egg based (IIV4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Afluria</td>
<td>Seqirus</td>
<td>0.25 mL PFS®</td>
<td>6–35 months</td>
<td>75 μg/0.25 mL dose</td>
<td>IM</td>
<td>--</td>
<td>No</td>
</tr>
<tr>
<td>Afluria</td>
<td>Seqirus</td>
<td>0.5 mL PFS®</td>
<td>≥3 years</td>
<td>15 μg/0.5 mL dose</td>
<td>IM</td>
<td>--</td>
<td>Yes</td>
</tr>
<tr>
<td>FluariX</td>
<td>GlaxoSmithKline</td>
<td>0.5 mL PFS®</td>
<td>≥6 months</td>
<td>15 μg/0.5 mL dose</td>
<td>IM</td>
<td>--</td>
<td>No</td>
</tr>
<tr>
<td>FluLaval</td>
<td>GlaxoSmithKline</td>
<td>0.5 mL PFS®</td>
<td>≥6 months</td>
<td>15 μg/0.5 mL dose</td>
<td>IM</td>
<td>--</td>
<td>No</td>
</tr>
<tr>
<td>Fluzone</td>
<td>Sanofi Pasteur</td>
<td>0.5 mL PFS®</td>
<td>≥6 months</td>
<td>15 μg/0.5 mL dose</td>
<td>IM</td>
<td>--</td>
<td>No</td>
</tr>
<tr>
<td>Fluzone</td>
<td>Sanofi Pasteur</td>
<td>0.5 mL MDV*</td>
<td>≥6 months</td>
<td>15 μg/0.5 mL dose</td>
<td>IM</td>
<td>25</td>
<td>No</td>
</tr>
<tr>
<td>Standard dose, cell culture based (ccIIV4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flucelvax</td>
<td>Seqirus</td>
<td>0.5 mL PFS®</td>
<td>≥4 years</td>
<td>15 μg/0.5 mL dose</td>
<td>IM</td>
<td>--</td>
<td>No</td>
</tr>
<tr>
<td>Flucelvax</td>
<td>Seqirus</td>
<td>5.0 mL MDV**</td>
<td>≥4 years</td>
<td>15 μg/0.5 mL dose</td>
<td>IM</td>
<td>25</td>
<td>Yes</td>
</tr>
<tr>
<td>High dose, egg based (HD-IIV4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluzone HD</td>
<td>Sanofi Pasteur</td>
<td>0.7 mL PFS®</td>
<td>≥65 years</td>
<td>60 μg/0.5 mL dose</td>
<td>IM</td>
<td>--</td>
<td>No</td>
</tr>
<tr>
<td>Egg based (LAIV4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FluMist</td>
<td>AstraZeneca</td>
<td>0.2 mL PFNS*</td>
<td>2–49 years</td>
<td>10 fluorescent focus units/0.2 mL</td>
<td>NAS</td>
<td>--</td>
<td>No</td>
</tr>
</tbody>
</table>

*PFS = Pre-Filled syringe  ** = Multi-Dose Vial  * = Pre-Filled Intranasal Spray  †IM = Intramuscular  ‡NAS = Nasal

(Contributed by: Matt Bobs, MPH, Pollyanna Stewart, MSN, RN-BC, and Alicia Wieber, Alaska Section of Epidemiology, Immunization Program.)